Business context and reporting period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a Solana Co filing. Helius develops the PoNS medical device for neurological conditions. It began accepting U.S. prescriptions in Q1; first U.S. commercial sales began in April 2022. PoNS was also sold in Canada.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless indicated otherwise.
- Revenue: $190,000, up from $84,000 year over year. Product sales were $183,000 versus $77,000; license revenue was $7,000 in both periods.
- Gross profit and margin: $66,000 versus $69,000; gross margin was approximately 35% versus 82%. Higher product costs included production ramp and supply-chain personnel costs.
- Operating expenses and loss: Operating expenses rose to $4.63 million from $3.57 million, including R&D of $1.76 million and SG&A of $2.82 million. Operating loss was $4.56 million versus $3.50 million; net loss was $4.35 million versus $3.36 million. Basic and diluted loss per share was $1.15 versus $1.65, with a higher weighted-average share count in 2022.
- Cash flow: Operating cash use was $4.68 million versus $2.92 million. Investing provided $4,000; financing used $17,000. Cash declined $4.70 million during the quarter.
- Cash and liquidity: Cash was $6.31 million at March 31, down from $11.01 million at year-end. Working capital was $5.83 million, versus $9.94 million. Current assets were $8.03 million and current liabilities $2.20 million.
- Debt and liabilities: The filing reports no borrowings. Total liabilities were $2.49 million, including $150,000 of operating lease liabilities and $219,000 of deferred revenue.
Material changes and notable items
- Revenue increased by $106,000, but gross profit decreased by $3,000 as cost of product sales rose to $124,000 from $15,000.
- Operating expenses increased by $1.06 million, primarily due to R&D product-improvement and clinical-development costs and additional personnel supporting the U.S. launch.
- Q1 2022 product sales included approximately $120,000 of PoNS devices delivered under the HTC agreement; the filing also says 16 devices transferred as acquisition consideration generated approximately $100,000 of revenue. These transfers contributed to reported sales and are important to distinguish from recurring customer demand.
- Foreign-exchange gain was $217,000, compared with $139,000; foreign-currency translation reduced comprehensive income by $202,000.
- Helius notified HTC of alleged material breaches of the Co-Promotion Agreement in January 2022 and states that, in its view, HTC’s exclusivity right is no longer effective. The parties were discussing potential future cooperation.
Outlook, risks and contingencies
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern. It expected existing capital to fund operations only into Q3 2022 and said additional equity or debt financing would be needed thereafter. It also cited the Lincoln Park equity facility, under which approximately $14.4 million remained available at quarter-end, subject to conditions; no shares were sold under it in Q1.
- Management expects ongoing operating losses and cash outflows. No specific revenue or profitability guidance is provided. If additional capital cannot be raised on acceptable terms, the company may reduce operations or capital spending, sell assets, or cease operations.
- Commercial execution depends on U.S. launch adoption, reimbursement and coverage, building commercial infrastructure, and manufacturing capacity. Management anticipated that broad government and private-payer coverage could take at least 24 months; prior Medicare Coverage of Innovative Technology rules were repealed, and future coverage rules were uncertain.
- COVID-related labor shortages and supply-chain disruptions delayed manufacturing and may constrain production, deliveries, and clinical work. Helius also relies on third parties for manufacturing and distribution.
- Planned clinical work included a U.S. MS therapeutic experience program expected to enroll approximately 40–50 patients, and a stroke trial planned to begin in the second half of 2022, subject to funding and execution.
- The filing reports no material pending legal proceedings. Management stated disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the provided document is for Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co.
- Assess the going-concern warning, cash runway, financing needs, and the availability and potential dilution from the Lincoln Park facility.
- Separate Q1 device transfers and HTC-related revenue from sales to independent customers; evaluate subsequent U.S. commercial sales after the quarter.
- Track manufacturing capacity, supplier delays, product quality, and the company’s ability to fulfill commercial and clinical demand.
- Verify progress on reimbursement, clinic and patient adoption, the HTC dispute, and funding and timing for planned clinical programs.